id-soluble vitamins. In the intestine, gut microbial bile salt hydrolases (BSH) deconjugate taurine-and glycine-conjugated-bile acids, and bacterial 7α-dehydroxylases convert primary bile acids CA and CDCA to deoxycholic acid (DCA) and lithocholic acid (LCA), respectively, which are re-conjugated to glycine or taurine.
Regulation of Bile Acid Synthesis
Bile acids are the end products of cholesterol catabolism in the liver. Bile acids facilitate biliary cholesterol and lipid secretion to form mixed micelles in the gallbladder.
Bile acids are reabsorbed in the ileum and transported via enterohepatic circulation (EHC) to the liver to inhibit bile acid synthesis by transcriptional repression of CYP7A1 and CYP8B1 gene expression. EHC is highly efficient, occurs several times a day and recycles about 95% bile acids. EHC of bile acids facilitate absorption of nutrients to the liver to be metabolized and redistributed to other tissues. Two mechanisms have been suggested for bile acid feedback regulation of bile acid synthesis. In the liver, bile acids activate FXR to induce a negative nuclear receptor small heterodimer partner (SHP) to inhibit CYP7A1 and Bile acid synthesis and regulation. Two bile acid synthesis pathways exist in the liver. The classic pathway is initiated by CYP7A1, while the alternative pathway is initiated by sterol 27-hydroxylase (CYP27A1). In humans, 2 primary bile acids are synthesized: CA and CDCA. For synthesis of CA, CYP8B1 is needed. Mitochondrial CYP27A1 catalyzes the steroid side-chain oxidation reaction. In the alternative pathway, CYP7B1 is involved in the synthesis of oxysterol intermediates, which are converted to bile acids, mainly CDCA, in hepatocytes. In mice, CDCA is converted to tauro-α-muricholic acid and then TβMCA as primary bile acids. Bile acids are secreted through the bile salt export pump, stored in the gallbladder, and secreted into the gastrointestinal tract and reabsorbed through apical sodium-dependent bile salt transporter in the ileum. In the colon, TCA and TDCA are first de-conjugated by bacterial BSH, and dehydroxylated by bacterial 7α-dehydroxylases to form the secondary bile acids, DCA and LCA, respectively. In the ileum, the bile acid efflux transporter, sinusoidal organic solute transporter α/β effluxes bile acids and circulates bile acids to the liver via the portal vein to inhibit bile acid synthesis. Two mechanisms have been suggested to inhibit CYP7A1 and CYP8B1 gene transcription. In the liver, bile acids activate nuclear receptor FXR to induce a negative nuclear receptor, SHP to inhibit CYP7A1 and CYP8B1 gene transcription. In the intestine, FXR induces FGF15, or FGF19 in humans, which is circulated to the liver to activate plasma membrane FGF receptor 4 (FHFR4)/βKlotho signaling to inhibit CYP7A1 gene transcription. TGR5 (Gpbar-1) is expressed in the ileum and colon. TGR5 activates cAMP signaling to stimulate GLP-1 secretion in enteroendocrine L cells. GLP-1 stimulates insulin secretion in pancreatic β cells to improve insulin sensitivity. Decreasing BSH activity in gut microbiota increases TβMCA, which antagonizes FXR activity to reduce FGF15/19 and stimulates bile acid synthesis in hepatocytes. Increasing BSH activity in gut microbiota reduces TMCA antagonism of FXR and stimulates FGF15/19 production to inhibit bile acid synthesis. Thus, the gut-to-liver axis plays a critical role in the regulation of bile acid synthesis and metabolic homeostasis. CYP8B1 gene transcription. In the intestine, FXR induces fibroblast growth factor 15 (FGF15), which is transported to the liver to activate hepatic FGF receptor 4 signaling to inhibit CYP7A1 gene transcription. The gut microbiota plays a critical role in pathogen defense, immunity and nutrient harvest. Bile acids inhibit gut bacterial overgrowth and the gut microbiota controls bile acid metabolism by the de-conjugation of bile acids by BSH and de-hydroxylation by 7α-dehydroxylases, thus controlling bile acid composition in the pool [3, 4] . The gut microbiota utilizes short chain fatty acids from dietary carbohydrates for energy metabolism and regulates glucose, lipid and energy metabolism in the liver, muscle and adipocytes. The gut microbiota also controls gut hormones/peptides release from the intestine, such as YY and glucagon-like peptide-1 (GLP-1). These hormones regulate insulin secretion from pancreatic β cells and in turn, glucose homeostasis. Dysbiosis has been associated with inflammatory bowel diseases, obesity and type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), cirrhosis and liver cancer [5] [6] [7] [8] .
Bile acid synthesis is regulated by circadian rhythms and the fasting and refeeding cycle [1, 9] . In mice, CYP7A1 and bile acid synthesis peaks right after entering the dark cycle and decreases in the midnight. In humans, bile acid synthesis peaks at 9 a.m. and midafternoon [10] [11] [12] . Circadian rhythms are influenced by feeding and diets [13] [14] [15] . CYP7A1 expression rapidly increases after feeding and decreases after fasting, while CYP8B1 is stimulated by fasting and decreased by feeding [16] . Thus, circadian expression pattern of these 2 regulatory enzymes determines the rate of bile acid synthesis and bile acid composition in the pool. Disruption of the circadian regulation of bile acid synthesis alters hepatic metabolism and homeostasis and contributes to diabetes and obesity [17] .
Bile Acid Receptor Regulation of Hepatic Metabolism
Bile acids regulate hepatic metabolism through the activation of FXR and TGR5 signaling. The role of FXR in the regulation of hepatic lipid and glucose metabolism has been studied extensively. The activation of FXR by bile acids and agonists reduces serum triglycerides and improves glucose tolerance and insulin resistance in diabetic mice [18, 19] . However, more recent studies show the opposite effect in that deficiency of FXR improves glucose homeostasis [20] and the activation of FXR lowers bile acid synthesis and induces obesity and diabetes [21] . Moreover, several recent studies show that deficiency of intestinal Fxr gene or antagonism of intestine FXR by the antioxidant tempol or intestine-selective FXR inhibitor Gly-MCA increases TMCA to antagonize intestinal FXR and decrease obesity and NAFLD [22] [23] [24] . Conversely, the activation of intestinal FXR by a selective FXR agonist fexaramine (FEX) also improves diabetes and obesity in mice [25] . Thus, the role and mechanism of FXR signaling in the regulation of lipid and glucose metabolism is controversial and not completely understood.
The role of TGR5 in the regulation of hepatic metabolism has not been studied in depth. TGR5 is widely expressed in many tissues including intestine, gallbladder, liver, and brain [26] [27] [28] . In the liver, TGR5 is expressed in Kupffer cells and sinusoidal endothelial cells, but not in hepatocytes [28, 29] . In the gastrointestinal tract, the activation of TGR5 by bile acids and agonists protects intestinal barrier function, reduces inflammation, and stimulates gallbladder refilling and GLP-1 secretion from enteroendocrine L cells [30] , which increases postprandial insulin secretion from pancreatic β cells and improves insulin resistance [31] . GLP-1 is an intestinal incretin produced in L cells through the processing of preproglucagon by prohormone convertase 1/3 (PC1/3) and is released in response to meal intake [32] . GLP-1 secretion is stimulated by nutrients in the intestinal lumen, such as carbohydrates, fats and proteins. The synthetic GLP-1 analog exendin-4 reduces hepatic steatosis by decreasing lipogenesis and inducing fatty acid oxidation [33] . The activation of TGR5 induces thyroid hormone deiodinase 2 to stimulate energy metabolism in brown adipose tissues [34] . The activation of TGR5 stimulates adenylyl cyclase to convert AYP to cAMP, which activates protein kinase A to activate the cAMP response elementbinding protein (CREB) and results in alleviation of obesity and hepatic steatosis in diet-induced obese mice [31] . Thus, further study of the role of FXR and TGR5 in hepatic metabolism and diabetes is needed.
Key Messages
FXR and TGR5 are co-expressed in intestinal endocrine L cells. It is possible that the activation of FXR may stimulate GLP-1 secretion from L cells and contribute to increasing insulin secretion from the pancreatic β cell to improve insulin sensitivity. To test this hypothesis, FXR and TGR5 agonists were used to study their effects on GLP-1 secretion in wild type, Fxr -/-and Tgr5 -/-mice, and in enteroendocrine GLUTag and STC-1 cells. Oral gavage of FXR agonists OCA, GW4064 and FEX, and TGR5 selective agonist INT777 agonist stimulated GLP-1 secretion in wild type mice and GLUTag cells. Real-time PCR assay showed that the 4 TGR5 mRNA expression level was induced in the intestine of wild type mice, but reduced in Fxr -/-mice, suggesting that FXR induced TGR5 gene transcription. Interestingly, mRNA levels of PC1/3, which splices preproglucagon to glucagon, were also induced by OCA and GW4064 and FEX, and reduced in Fxr -/-mice. Immunoblot analysis showed OCA and FEX induced TGR5 and PC1/3 protein levels in mouse ileum. CREB reporter assay and site-directed mutagenesis identified an FXR response element located in the proximal promoter of human and mouse Our data also showed that OCA and FEX have differential effects on hepatic glucose and lipid metabolism; FEX is more effective in inhibiting gluconeogenesis and improving glucose tolerance, while OCA is more effective in stimulating fatty acid oxidation and improving lipid metabolism. This study also indicated that GLP-1 may directly stimulate insulin-like signaling in hepatocytes to inhibit gluconeogenesis and improve insulin and glucose sensitivity. FEX inhibits hepatic gluconeogenic gene expression and improves insulin and glucose tolerance and reduced serum cholesterol and hepatic triglycerides in diabetic db/db mice.
Conclusions
The gut-to-liver axis plays a critical role in regulating bile acid synthesis and FXR and TGR5 signaling in liver and intestine. The activation of FXR by bile acids in the intestine induces FGF15 to inhibit bile acid synthesis in the liver, whereas the inhibition of BSH by gut bacteria or the antioxidant tempol increases T-β-MCA, which may antagonize FXR and FGF15 production to stimulate bile acid synthesis [22, 35] . In mice deficient of intestinal Fxr , FGF15 production is reduced and bile acid synthesis is upregulated to stimulate hepatic FXR and improve glucose and insulin sensitivity, and thus prevent diet-induced NAFLD [23] . The intestine-selective inhibition of FXR by Gly-MCA also reduces intestine ceramide production and contributes to improving diabetes and obesity [24] . Disruption of the gut-to-liver axis by deleting or inhibiting intestinal FXR or treating with antibiotics, alters gut microbiota to increase ileum TMCA and bile acid synthesis to regulate glucose and lipid metabolism and prevent diet-induced diabetes and obesity. On the other hand, pharmacological activation of intestinal FXR may reduce TCA and increase LCA to stimulate FGF15 and GLP-1 production to improve hepatic metabolism and insulin and glucose sensitivity. Intestinal FXR and TGR5 signaling crosstalk may coordinately stimulate GLP-1 secretion to improve hepatic glucose and insulin sensitivity in diabetes. FXR and TGR5 dual agonists may be effective for treating liver-related metabolic diseases, diabetes and NAFLD.
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